[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495048":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":53,"centralContacts":58,"locations":64,"responsibleParty":81,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":62,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":62,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":62,"overallStatus":66,"whyStopped":62,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Shanxi Bethune Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Selinexor、HAD or CAG regimens","EXPERIMENTAL","* Selinexor (60 mg) is used twice weekly for two weeks (four times, 240 mg total of selinexor) in combination with HAD or CAG regimens for reinduction therapy in patients with relapsed and refractory AML.\n* (Bone marrow image indicates active hyperplasia) HAD regimen: homoharringtonine (HHT) (2mg\u002F m\\^2\u002Fd)×7days, daunorubicin (DNR, 40mg\u002F m\\^2\u002Fd)×3 days, cytarabine (Ara-C,100-200mg\u002F m\\^2\u002Fd)×7 days (no leukocyte drugs should be used throughout the treatment process)；\n* (Bone marrow image indicates hypoproliferation)CAG regimen: Granulocyte Colony-Stimulating Factor (G-CSF, 5ug\u002Fkg\u002Fd, started 12 hours before chemotherapy×14 days (d1-d14), aclacinomycin (20mg\u002Fd)×4 days (d1-4), cytarabine (10 mg\u002F m\\^2, subcutaneous injection, 1 time in 12 hours)×14 days (d1-d14).\n* G-CSF was discontinued in the CAG regimen when WBC \\> 20×10\\^9\u002FL, but chemotherapy was not stopped.",[13,14,15,16,17,18],"Drug: Selinexor","Drug: Homoharringtonine","Drug: Daunorubicin","Drug: Cytarabine","Drug: Granulocyte Colony-Stimulating Factor","Drug: Aclacinomycin",[20,27,33,38,43,48],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Selinexor","Given PO",[9],[26],"KPT-330",{"type":21,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Homoharringtonine","Given per standard of care",[9],[32],"HHT",{"type":21,"name":34,"description":29,"armGroupLabels":35,"otherNames":36},"Daunorubicin",[9],[37],"DNR",{"type":21,"name":39,"description":29,"armGroupLabels":40,"otherNames":41},"Cytarabine",[9],[42],"Ara-C",{"type":21,"name":44,"description":29,"armGroupLabels":45,"otherNames":46},"Granulocyte Colony-Stimulating Factor",[9],[47],"G-CSF",{"type":21,"name":49,"description":29,"armGroupLabels":50,"otherNames":51},"Aclacinomycin",[9],[52],"ACM",[54],{"name":55,"affiliation":56,"role":57},"Tao Wang","Shanxi Bethune Hospital Regulatory Authority","STUDY_DIRECTOR",[59],{"name":55,"role":60,"phone":61,"phoneExt":62,"email":63},"CONTACT","13835175119",null,"wangtao99699@163.com",[65],{"facility":55,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"RECRUITING","Taiyuan","Shanxi","030000","China","CN",{"type":73,"coordinates":74},"Point",[75,76],112.56028,37.86944,{"lat":76,"lon":75},[79],{"name":80,"role":60,"phone":61,"phoneExt":62,"email":63},"Tao Wang, doctorial",{"type":82,"investigatorFullName":62,"investigatorTitle":62,"investigatorAffiliation":62,"oldNameTitle":62,"oldOrganization":62},"SPONSOR",[84],{"name":85,"class":86},"Antengene Corporation","INDUSTRY","100495048","phase-3-selinexor-in-combination-with-had-or-cag-rregimens-in-relapsed-or-refractory-acute-myeloid-leukemia-100495048",false,"NCT05726110","Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia","A Single-arm Open-label Multicenter Clinical Study of Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia","Inclusion Criteria:\n\n1. Age:18-60 years old;\n2. Except for patients with AML-M3 with acute myeloid leukemia；\n3. Meet the diagnostic criteria for refractory AML (2011 Chinese guidelines for the diagnosis and treatment of acute myeloid leukemia (relapsed or refractory)):(1) The standard regimen did not achieve complete remission after 2 courses of induction chemotherapy;(2) Relapse within 6 months after the first complete remission; (3) Patients who relapse after 6 months after the first complete remission, and those who fail to induce chemotherapy after the original program; (4) 2 or more recurrences; (5) Extramedullary leukemia persists；\n4. Meet the diagnostic criteria for recurrent AML (refer to the 2014 NCCN guidelines): after complete remission, (1) naive cells appear in peripheral blood; (2) \\>5% of bone marrow naive cells; (3) Extramedullary recurrence；\n5. The bone marrow image indicates active hyperplasia or hypoproliferation；\n6. Eastern Oncology Collaborative Group Physical Status Assessment (ECOG-PS) with a score of 0-2.\n\nExclusion Criteria:\n\n1. Accompanied by cerebral hemorrhage；\n2. Pregnancy；\n3. Have a mental illness or other condition that cannot proceed as planned；\n4. Severe arrhythmia, abnormal ECG (QT\\>500ms).\n\nEarly withdrawal from test criteria：\n\nParticipants have the right to withdraw from the study at any time from the trial. Exit Criteria:\n\n1. The subject or the subject's legally authorized representative requests to withdraw from the study;\n2. Participant loss to follow-up.\n\nDoctor\u002FInvestigator required subjects to terminate the trial early:\n\n1. Subjects who are unable to carry out follow-up treatment due to adverse events (serious irreversible organ function damage during treatment) who are judged by the investigator to be unsuitable for continuing the research;\n2. The subject does not adhere to the protocol, such as the use of chemotherapy drugs, etc., which affects the effectiveness and safety judgment.\n\nFor participants who withdrew early from the study (except subjects who were lost to follow-up), the reason for their early withdrawal should be recorded, and the time of the last study's medication\u002Ftreatment should be recorded, and the examination items at the time of early withdrawal from the study should be completed at the last visit, if possible.","ALL","18 Years","60 Years",{"count":98,"type":99},50,"ESTIMATED","INTERVENTIONAL",[102],"PHASE3","This clinical trial studies the efficacy and safety of selinexor combined with HAD or CAG regimen in the treatment of relapsed or refractory acute myeloid leukemia",[105],"Relapsed or Refractory Acute Myeloid Leukemia","2024-10-20",{"date":108,"type":109},"2024-10-22","ACTUAL",{"date":111,"type":109},"2023-01-29",{"date":113,"type":99},"2024-12-31",{"name":5,"class":6},1]